VERA THERAPEUTICS, INC. 7,142,858 Shares of Class A Common Stock Underwriting AgreementVera Therapeutics, Inc. • October 31st, 2024 • Pharmaceutical preparations • New York
Vera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“J.P. Morgan”), Goldman Sachs & Co. LLC (“Goldman Sachs”), Evercore Group L.L.C. (“Evercore”) and Cantor Fitzgerald & Co. (“Cantor”) are acting as representatives (the “Representatives”), an aggregate of 7,142,858 shares (the “Underwritten Shares”) of Class A common stock, par value $0.001 per share, of the Company and, at the option of the Underwriters, up to an additional 1,071,428 shares of Class A common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Class A common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
